1 HEARING DAY 2

2 TRIUMF: Application for a licence to operate 3 Class I and Class II particle accelerator 4 facilities at its site in Vancouver, British 5 Columbia

6 We will now move to Item 3 of the 7 agenda which is Hearing Day 2 on the matter of the 8 application by TRIUMF for an application for a 9 licence to operate Class I and Class II particle 10 accelerator facilities.

11 The first day of the public 12 hearing on this application was held December 13, 13 2001. The public was invited to participate, 14 either by oral presentation or written submission 15 on Hearing Day 2.

16January 29th was the deadline set17for filing by intervenors. No requests for18interventions were filed.

19A notice of Public Hearing202001-H19 was published on October 8, 2001. The21Commission Members present for Day One of the22Hearing included Mr. Graham, Dr. Giroux,23Ms MacLachlan and myself.24As in Day 1 of the hearing,

25 Dr. Barnes has excused himself from participating

StenoTran

in this hearing in relation to this application. 1 Dr. Barnes is on the faculty of the University of 2 3 Victoria and the University is one of the participants in the joint venture. 4 Presentations were made on Day One 5 by Commission staff under CMD 01-H34 and CMD 6 01-H34.A. I note that both the applicant and CMD 7 staff will present supplementary information 8 9 today. I would like to begin by calling 10 on the TRIUMF group for their oral presentation as 11 outlined in CMD document 01-H34.1. 12 13 I note that there is a number of 14 TRIUMF representatives with us today. I believe 15 Dr. McDonald will start. Good morning. 16 17 18 01-H34.1/01-H34-1A 19 Oral presentation by TRIUMF Madam Chairman, 20 DR. SHOTTER: 21 Members of the Commission. May I introduce the delegation from TRIUMF? 22 John McDonald is the Chairman of 23 the Board of Management of TRIUMF. 24 25 Feridun Hamdullajhpur is Chairman

StenoTran

of the Safety Commission -- sorry, Chairman of the 1 Safety Committee of the Management Board, and Lutz 2 3 Moritz is the Management Officer of the Health and Safety Committee of TRIUMF, and I am the Director 4 of TRIUME itself. 5 6 The presentation will be made by Lutz Moritz. 7 MR. MORITZ: At the December 13th, 8 2001 meeting of the Canadian Nuclear Safety 9 Commission, the TRIUMF application for a renewal 10 of its operating licence received its first public 11 12 hearing. 13 At that hearing CNSC staff 14 presented a summary of their findings related to the TRIUMF application. These findings were 15 largely positive, showing that TRIUMF was in 16 17 compliance with all existing licence conditions. 18 However, at that meeting the 19 Commissioners were sufficiently concerned about a number of issues to request that TRIUMF make a 20 21 presentation at the second public hearing today. So this presentation will try to 22 address the issues of concern raised at that first 23 24 hearing. 25 First of all, we would like to

StenoTran

offer a brief introduction of TRIUMF. 1 TRIUME is Canada's National 2 3 Laboratory for Particle and Nuclear Physics. Under the NRC Contribution Agreement, TRIUMF has 4 responsibility for supporting the accelerated 5 6 radioactive ion beams program and the base program on 500 MeV cyclotron, as well as providing 7 infrastructure support for the Canadian Subatomic 8 Science Community and contributions to 9 international accelerator projects. 10 TRIUMF has also been highly 11 successful in its effort to pursue applications of 12 13 the technology developed at TRIUMF. 14 The accelerator facility located on the campus of the University of British 15 Columbia is based on a cyclotron that accelerates 16 17 negative hydrogen ions to a peak energy of 520 18 MeV. TRIUMF also operates two radioisotope 19 productions cyclotrons: a 42 MeV cyclotron and a 20 30 MeV cyclotron for MDS Nordion. 21 A fourth cyclotron with a maximum proton energy of 13 MeV is operated by the TRIUMF 22 23 Life Sciences program in collaboration with the University of British Columbia Health Sciences 24 25 Centre and is used for the production of

StenoTran

radioisotopes for positron emission tomography. 1 The ISAC facility at TRIUMF uses a 2 3 linear accelerator system to accelerate radioactive ion beams to energy is up to 1.6 MeV 4 5 per atomic mass unit. 6 The programs and TRIUMF support the activities of some 500 users drawn from the 7 international scientific community. 8 TRIUMF also provides 9 10 infrastructure support for particle physics experiments in Canada and in a number of 11 accelerated facilities around the world. 12 13 The acceleration of negative 14 hydrogen ions in the 500 MeV cyclotron shown at 15 the centre of this slide, make possible the extraction of multiple proton beams of variable 16 17 energy. 18 These proton beams may be directed towards five distinct areas that differ in the way 19 the proton beam is utilized: The Meson Hall for 20 21 the production of pi-meson and muon beams; the Proton Hall for nucleon-nucleon scattering 2.2 23 experiments; ISAC for the production of 24 radioactive ion beams; the Proton Therapy Facility for treatment of intra-ocular tumours; the Proton 25

StenoTran

Irradiation Facility for material radiation damage 1 studies, and the 2C Irradiation Facility for the 2 3 production of radioisotopes for medicine. In this plan view of TRIUMF also 4 shown are the 42 MeV radioisotopes cyclotron and 5 the 30 MeV cyclotron and the 13 MeV cyclotron. 6 We will now describe some aspects 7 of the organizational structure of TRIUMF. 8 TRIUMF is operated as a joint 9 venture of five universities: the University of 10 Alberta, the University of British Columbia, 11 Carleton University, Simon Fraser University and 12 13 the University of Victoria. Six other universities have associate status in the 14 consortium: The University of Manitoba, McMaster 15 University, l'Université de Montréal, Queen's 16 University, the University of Regina, and the 17 18 University of Toronto. The TRIUMF Board of Management is 19 appointed by the member universities to operate, 20 supervise and control TRIUMF. The Board's primary 21 duties include policy making and determination of 22 23 the budget, facilities planning and funding for

24 the laboratory.

25

One member of the Board is

StenoTran

б

designated to monitor safety issues at TRIUMF. 1 The TRIUMF Board selects the Director and appoints 2 3 the members of the Operating Committee on the advice of the Director. 4 For operational purposes, TRIUMF 5 has been organized into a number of functional 6 divisions whose heads are responsible to the 7 Director. The divisions are further subdivided 8 into groups which have responsibility for various 9 10 systems and operations. Experiments are assigned priority 11 by the Experimental Evaluation Committee and they 12 13 are scheduled by the Associate Director who also heads the Science Division. 14 The Director receives administrative support from the staff of the 15 Administration Division and the role of the Safety 16 Management Committee that interacts with the 17 18 Director we will discuss in the next slide. At TRIUMF safety is recognized to 19 be a line responsibility. Each Line Supervisor is 20 directly responsible for the safety of those under 21 2.2 him. 23 Ultimate responsibility for the 24 safety requirements in the design, construction, 25 and operation of facilities within the laboratory

StenoTran

rests with the Director. The Director delegates
 this responsibility to the heads of the various
 line organizations, and through them to the
 supervisors.

Supervisors are held directly
accountable through line authority to the Director
for the safety of their operation.

Safety issues are addressed at the 8 quarterly meetings of the TRIUMF Safety Management 9 Committee. This committee is composed of the 10 heads of the TRIUMF divisions, the Chair of the 11 TRIUMF Accident Prevention Committee, the Manager 12 13 of the Office of Environmental Health and Safety 14 and the heads of the three operations groups and is chaired by the Director of TRIUMF. 15

The members with operational and safety oversight responsibilities provide reports of the safety status of the facility at these meetings, and the Director assigns any outstanding issues to the responsible division head for resolution.

22 The Board of Management monitors 23 the safety status of TRIUMF through its 24 Environmental Safety and Security Committee. 25 We will now describe in more

StenoTran

detail the arrangement that exist between the 1 universities that govern TRIUMF. 2 3 In January 1966, the University of British Columbia supplied the initial tract of 4 land on which TRIUMF is located in order to build 5 a cyclotron accelerator facility for research 6 7 purposes. At that time there were three 8 participating universities hence the name 9 10 Tri-University Meson Facility, or TRIUMF: The University of British Columbia, Simon Fraser 11 University and the University of Victoria. 12 In 13 1968 the University of Alberta became the fourth 14 member of the TRIUMF consortium. 15 The question of an appropriate organizational structure was an issue of serious 16 17 consideration from the outset. In the period from 18 March 1975 to November 1981, various models 19 including incorporation and the joint venture model were extensively explored. The joint 20 venture model was eventually formally adopted on 21 November 3, 1981. 22 23 When the Joint Venture Agreement was amended as of March 2000 to include Carleton 24

25 University as a full member, the joint venture

StenoTran

model was found to be still appropriate. 1 2 Under the Joint Venture Agreement 3 each participating university owns an equal, undivided interest in all assets, including 4 intellectual property, and has an equal 5 responsibility for liabilities. 6 The Director of TRIUMF arranges 7 for adequate and proper insurance protection 8 against all property loss and against liabilities. 9 The policies protect the Governors of the 10 participating universities in the joint venture 11 and all appointees acting on behalf of TRIUMF. 12 13 The Director presents the 14 insurance program of TRIUMF and any 15 recommendations for changes to that program to the Board at least once per year. 16 17 The agreement specifies that at 18 any time during the life of TRIUMF any of the universities may withdraw from TRIUMF on one 19 year's notice. The agreement would then be 20 21 changed and modified when necessary to reflect the reduced number of universities participating in 22 23 TRIUMF. The university that has withdrawn 24 25 will not be responsible for any liabilities that

StenoTran

rise out of activities of TRIUMF after the expiry 1 of the notice of withdrawal, but will remain 2 3 liable in respect of any liability that may arise out of activities of TRIUMF prior to the notice of 4 withdrawal. The remaining universities will be 5 equally responsible for any liabilities incurred 6 after the date of notice of withdrawal. 7 The University of British Columbia 8 would retain right in the land and buildings used 9 by TRIUMF in the event of their withdrawal. 10 In the event of the termination of 11 TRIUMF, no further business would be transacted 12 13 except such as might be necessary for the winding up of TRIUMF affairs and distribution of assets. 14 The Board would continue to serve until the 15 completion of the winding up of TRIUMF. 16 In the event of the termination of 17 18 TRIUMF, the affairs of TRIUMF would be wound up 19 and liquidated as promptly as business circumstances and orderly business practices 20 21 permit. Under the agreement, each of the 2.2 23 participating universities agrees that it shall work with the University of British Columbia and 24 25 the other universities to address any

StenoTran

environmental issues that may arise out of the
 termination of TRIUMF.

We would now like to say a few words and make some comments on the relative magnitude of the hazard posed by the TRIUMF operation.

7 The hazards associated with the 8 operation of TRIUMF are for the most part similar 9 to those encountered in the operation of other 10 light industries. Among these hazards, the use of 11 high-voltage and high-current electrical devices 12 and overhead materials hoists are probably the 13 most significant.

14 The radiological hazards of TRIUMF consist of the prompt radiation due to interaction 15 of the accelerated protons with matter and of the 16 induced radioactivity generated by these 17 18 interactions. Both of these are proportional to 19 the power in the accelerated beams of particles. 20 This slide shows how TRIUMF fits 21 into the regulatory structure of the Nuclear Facilities Regulation. The TRIUMF 500 MeV 22 23 facility is designated as a nuclear facility Class IB. The regulations that govern nuclear 24 25 facilities Class IA which apply to power reactors

StenoTran

and nuclear facilities Class IB, which among 1 others apply to accelerators with energy greater 2 3 than 50 MeV have most elements in common and these have common requirements. 4 The one difference in the 5 6 regulation is the requirement for certification of certain personnel for Class IA facilities. 7 As we saw in a previous slide, the 8 total radioactivity induced in a proton 9 accelerator, that is all the radioactivity induced 10 in the structure and in any targets or beam dumps 11 is approximately proportional to the power in the 12 13 accelerated beams. 14 The proportionality may be expressed as approximately six terabecquerels at 15 saturation per kilowatt of beam power. Although 16 17 this represents an overestimate by perhaps a 18 factor of two for accelerators with proton energies less than a few hundred MeV. 19 20 The power average over the long 21 term in the proton beams produced at the TRIUMF 500 MeV cyclotron is less than 100 kilowatts and 22 23 thus the total radioactivity induced in the facility is of the order of 600 terabecquerels. 24 25 In comparison the radioactivity

StenoTran

inventory of a typical power reactor is 1 approximately 50 terabecquerels per kilowatt. 2 Α 3 typical 1000 megawatt power reactor therefore has a radioactivity inventory of 50 million 4 terabecquerels about a 100,000 times greater than 5 The radioactivity produced by the 500 MeV 6 TRIUMF. cyclotron is almost entirely induced in solid 7 structures and hence is non-volatile and cannot be 8 accidentally released to the environment. 9 Let us now turn to specific issues 10 that were raised at the first hearing. 11 These included comments on the safety culture at TRIUMF 12 13 and questions on operator training, quality 14 assurance, decommissioning and housekeeping. I'm 15 getting ahead of myself here a little bit. So safety culture at TRIUMF was 16 17 independently evaluated last year by a team of 18 consultants commissioned by the CNSC. The 19 evaluation was generally very positive as exemplified by the following quotations taken from 20 21 the summary of the report submitted to the CNSC by 2.2 the consultant. 23 "Employees interviewed and surveyed across the TRIUMF 24

StenoTran

facility described the

25

1 organization as a safe place to work and one that places a 2 3 high priority on environment, safety and health issues. 4 Employees perceive the 5 organization to pay attention 6 7 to the values, attitudes and 8 behaviours important to safe 9 performance. 10 Management places a high 11 level of emphasis on environment, safety and 12 13 health issues. 14 Employees are generally aware 15 of these issues." 16 The positive safety culture is also illustrated in this figure taken from the 17 18 report which summarizes the responses to questions concerning safety awareness of staff and how they 19 20 perceive the hazard both on site and the potential 21 impact off site. The vertical scale on this graph 22 is the rating given in response with a possible 23 range from one to seven. The first two points summarize the 24 25 responses on perceived risks with seven

StenoTran

corresponding to the highest level of perceived 1 The low rating on these points shows that 2 risk. 3 TRIUMF staff recognize and understand that both the hazard of working at TRIUMF and the possible 4 off site impact are low. They correctly reflect 5 that the ISAC facility has perhaps the greatest 6 potential for hazard as it produces some volatile 7 radioactive material. 8

The second two points summarize 9 10 the answer to the question concerning how TRIUMF staff perceives management emphasis on safety or 11 risk management and the level of awareness by 12 13 employees of the safety issues. A high score here 14 indicates a high level of emphasis and a high level of awareness. The score showed that the 15 awareness of safety issues by both management and 16 employees across all divisions at TRIUMF is at the 17 18 same high level despite the recognition that the 19 risks are low. The highest emphasis and awareness is also correctly put on the ISAC facility where 20 21 the risk is perceived as being greatest.

22 Now, we turn to the question of 23 operator training. After the introduction of the 24 NSC regulations, CNSC staff examined the TRIUMF 25 operator training program and found it to be

StenoTran

generally acceptable, except that it was not as 1 well documented as they thought desirable. 2 3 CNSC staff requested at the time to follow a systematic approach to training. 4 Since then, TRIUMF has submitted a training plan 5 to the CNSC and has invested considerable effort 6 and made significant progress in formalizing the 7 operator training program using this approach. 8 TRIUMF recognizes the need for continued 9 improvements and is committed to making its 10 training program more transparent to outside 11 12 scrutiny.

13 In fact, the training of the crews 14 involved in operating the accelerators has always 15 been a high priority at TRIUMF. In the past, operators were trained primarily by job shadowing 16 17 that lasted approximately six months. The 18 trainees joined a number of different shifts to obtain a balanced view and to learn procedures 19 20 relevant to round-the-clock operation. Shifts 21 dedicated specifically to operator training are 22 regularly scheduled. During more than 25 years of 23 operation, there have been no incidents due to operator error that resulted in radiation 24 25 exposures greater than a small fraction of the

StenoTran

TRIUMF administrative control level or that had 1 2 any measurable radiological off site impact. 3 That this training has been highly effective is also demonstrated by the fact that 4 the availability of the accelerators is 5 6 consistently greater than 90 per cent, a very high figure when compared to other accelerator 7 laboratories. 8 A training plan for the 9 accelerator operators has set March 31st 2002 for 10 a completion date for the analysis phase. 11 This phase is ahead of schedule and we expect to meet 12 13 the milestone. The design of the training program 14 has started and a completion date for this phase has been set as May 1st 2002. Once the design has 15 been completed so that the resource requirements 16 are better to find, milestones will be set for the 17 18 development and implementation of the program. Another issue that has been raised 19 is the question of quality assurance. 20 TRIUMF is 21 highly committed to quality in all aspects of the operation. The quality of the scientific output 22 23 as judged by the international physics community has consistently been at the highest level. 24 We have described the details of how TRIUMF achieves 25

StenoTran

quality in the design and operation of its 1 facility in our submission for a licence renewal. 2 3 In this connection we might mention the report of the NRC Peer Review 4 Committee, which in 1999 reported that: 5 "By its high world-wide 6 visibility, TRIUMF is perhaps 7 the major scientific facility 8 9 that materializes Canada's status as one of the advanced 10 G-7 countries on the 11 scientific scene." 12 The requirement for a quality 13 14 assurance program is new under the NSC 15 requlations. TRIUMF has formed a task force to address the question of better defining the 16 17 quality assurance program at the laboratory. 18 TRIUMF is committed to complying with the 19 regulations and finding ways to improve the 20 quality of all aspects of the operation. 21 Next we turn to the issue of decommissioning. TRIUMF management is aware that 22 23 as a responsible organization it must plan for the eventual decommissioning of all or parts of the 24 25 laboratory. In order to develop a defensible plan

StenoTran

and cost estimates, TRIUMF has therefore 1 commissioned an independent consultant to develop 2 3 such a plan. An amount of \$225,000 has been budgeted for the work currently under way, which 4 is expected to be completed by mid-2002 and to be 5 submitted to the CNSC by September 2002. 6 Based on the estimates from this 7 study, Industry Canada will be asked to supply a 8 letter of guarantee to CNSC. In the interim, 9 TRIUMF has a copy of a letter from the President 10 of NRC, Dr. Carty, dated April 2nd 1996, sent to 11 the President of the University of British 12 13 Columbia stating that: 14 "In the event that 15 decommissioning becomes necessary, NRC agrees to use 16 its best efforts to bring 17 18 this issue to the attention of the federal government for 19 resolution." 20 The liability for decommissioning TRIUMF would 21 rest with the universities if there was no funding 22 23 from the federal government. 24 CNSC staff in their report brought 25 up the issue of housekeeping. At TRIUMF we work

StenoTran

diligently to maintain an acceptable standard of housekeeping. It must be said that the housekeeping issues at a dynamic research facilities where the installation is in constant flux are more complex than at a facility dedicated to producing a fixed product.

The TRIUMF Accident Prevention 7 Committee inspects this site on a monthly basis 8 and issues deficiency notices to supervisors who 9 10 do not comply with the expected standard. These deficiencies are most often quickly resolved but 11 are also reviewed at the quarterly safety 12 13 management meetings. Any unresolved issues 14 require prompt attention -- require prompt action, I should say, by the responsible division heads. 15

17 improvement in all matters affecting safety. A 18 new housekeeping task force has recently been 19 given oversight responsibility for assuring that 20 all housekeeping matters are promptly addressed.

16

A measure of the effectiveness of the TRIUMF occupational health and safety program is the rate classification applied by -- to TRIUMF, rather, by the Workers' Compensation Board of British Columbia. Despite the presence of

StenoTran

We remain committed to continuous

significantly greater hazards than on the typical 1 university campus in British Columbia, TRIUMF's 2 3 premium rate classification has been reduced from that applied to light industries, to that applied 4 to other universities in British Columbia. 5 But. because of a history of low claims, TRIUMF has its 6 premium rate further discounted by more than 7 14 per cent from the base rate for universities. 8

I would like to now summarize by 9 10 indicating that TRIUMF management and staff place a high priority on environment health and safety 11 issues and are continually seeking to improve the 12 13 standard of safety. TRIUMF is actively pursuing 14 compliance with the latest regulatory requirements as they apply to training, quality assurance and 15 decommissioning. 16

The ultimate measure of success of the safety program as far as concerns radiological safety is the dose to the workers at TRIUMF. TRIUMF has been able to reduce the dose to workers while at the same time increasing both the number of accelerators on site and their output. This is demonstrated in the following graph.

24 In this graph the total power in 25 all the particle beams of the accelerators at

StenoTran

1 TRIUMF is plotted as a function of time. 2 Superimposed is the collective dose for TRIUMF 3 workers also as a function of time. During the 4 initial learning curve, the collective dose 5 increased as the power in the accelerator beams 6 was increased.

Much development aimed 7 specifically at reducing the dose to personnel 8 that maintain and service the accelerators after 9 10 high intensity operation was carried out over a short period resulting in both enhanced 11 reliability of the cyclotrons and an improvement 12 of the handling of radioactive components. 13 These 14 developments have been applied to the design of 15 new cyclotrons installed at TRIUMF and elsewhere.

As a result, there has been a steady decline of the annual collective dose to TRIUMF personnel. At the same time, several new facilities have been installed and production has continued to increase.

21 That concludes our presentation,22 Madam President.

23THE CHAIRPERSON: Thank you very24much.

25

With the permission of the

StenoTran

Commission members I would like to turn to the 1 CNSC staff for their presentation before we open 2 3 the floor to questions. In that regard I would like to turn to CNSC staff, specifically as 4 outlined in CMD Document 01-H34.B and I will turn 5 to Mr. Howden who is Acting Director General of 6 Nuclear Cycle and Facilities Regulation. 7 Mr. Howden. 8 9 01-H34.B 10 Oral presentation by CNSC staff 11 MR. HOWDEN: Madam Chair, members 12 of the Commission, for the record my name is 13 14 Barclay Howden. I'm the Acting Director General 15 of the Directorate of Nuclear Cycle and Facilities Regulation. With me today are Dr. Aly Aly, 16 Director of the Research and Production Facilities 17 18 Division and Mr. John Power, Head of the New Projects Licensing Section within the same 19 20 division. 21 At Day One of this hearing on December 13th 2001, CNSC staff presented CMD's 22 01-H34 and 01-H34.A to the Commission. Since then 23 CNSC staff has submitted a supplementary CMD 24 25 01-H3.B that provides additional information in

StenoTran

response to Commission member questions raised on
 Day One.

With regard to training, TRIUMF has submitted a revised action plan that CNSC staff finds to provide an adequate basis for developing the needed training program using a systematic approach to training. CNSC staff finds the program to be ambitious and will be monitoring the implementation progress closely.

10 For this issue and others, if the proposed licence is issued by the Commission, CNSC 11 staff proposes to update the Commission on the 12 13 licensee's performance in one year's time. This update would be in addition to another status 14 15 report later in the licence term that would be done to comply with the CNSC staff's new approach 16 17 to flexible licence terms that has just been 18 finalized.

For the joint venture agreement, CNSC staff is satisfied that the current organizational structure and arrangements for management control and accountability in relation to the operation of the TRIUMF facilities are acceptable for the purposes of the Nuclear Safety and Control Act.

25

StenoTran

1 The CNSC staff conclusions and 2 recommendations remain unchanged. That is, the 3 licensee's operating performance has been acceptable during the current licence period. 4 The licensee's application for a new licence meets the 5 6 requirements of the Nuclear Safety and Control Act and its regulations, with the exception of the 7 quality assurance program and preliminary 8 decommissioning plan for which there are two 9 10 licence conditions proposed. And the applicant is qualified to carry on the activity that the 11 licence will authorize and will, in carrying on 12 13 that activity, make adequate provision for the 14 protection of the environment, the health and safety of persons and the maintenance of national 15 security and measures required to implement 16 17 international obligations to which Canada has 18 agreed. The CNSC staff recommends that the 19

20 Commission revoke TRIUMF's current licences and 21 issue a consolidated Class IB particle accelerator 22 operating licence for a five year term. 23 CNSC staff is prepared to answer 24 any questions you may have.

25 THE CHAIRPERSON: Thank you,

StenoTran

1 Mr. Howden.

| 2 | The floor is now open for |
|----|--|
| 3 | questions from the Commission members. |
| 4 | Mr. Graham. |
| 5 | MEMBER GRAHAM: Thank you. |
| б | This morning we have, I guess, |
| 7 | received quite a few assurances and some definite |
| 8 | time lines and my question first, I believe, would |
| 9 | be to CNSC staff. |
| 10 | In H-34.B you have said that there |
| 11 | will be a reporting on performance in one year by |
| 12 | March 31st 2003. If this licence had been a |
| 13 | five-year licence given a couple of years ago, |
| 14 | would you have been able to flag these problems |
| 15 | the same way and see the need for reporting within |
| 16 | one year like you are committing to this morning? |
| 17 | I guess what I am trying to ask is |
| 18 | on December 13th the Commission well raised, I |
| 19 | think, some fairly serious questions. Those |
| 20 | questions this morning have been addressed to a |
| 21 | certain extent. There will be questions on them |
| 22 | again but my concern is that if those if there |
| 23 | had not been an appearance before the Commission |
| 24 | at that time, would we have been able to be on top |
| 25 | of the situation like we are today? |

StenoTran

MR. HOWDEN: Dr. Aly will respond 1 2 to that question. 3 DR. ALY: In our current approach we have plans to provide updates to the Commission 4 on performance of all Class I and Class II 5 facilities. We did that last year for all 6 radioisotope processing facilities. It was in the 7 late fall and we plan to continue doing that for 8 the rest of the facilities. There will be 9 10 periodic reporting on licensee's performance. MEMBER GRAHAM: But my question, 11 and that is still kind of not answering it the way 12 13 I understand it. 14 If TRIUMF hadn't been before us, if they had not been before us on December 13th, 15 would you have still been aware of all of the 16 serious situations that -- if there hadn't been an 17 18 application, would you have been aware of the seriousness of some of the questions that were 19 20 approached on that December 13th hearing? 21 DR. ALY: The answer to that is yes because we have already activities in progress 22 23 regarding all the issues. We are communicating 24 with the licensee on that and there are programs 25 in place. And this we are going to proceed with

StenoTran

or without a hearing. 1 What I mentioned before is we were 2 3 going to report to the Commission periodically on all licensee performance. But yes, the answer is 4 5 yes. Because the 6 MEMBER GRAHAM: applicant has come, you know, with some pretty 7 specific deadlines for certain things and I'm 8 wondering if those specific deadlines, and I 9 believe one of them is October 2002 and one is 10 November 2002 this year, that they will address 11 these issues. Would they have been given those 12 13 same deadlines? 14 DR. ALY: The answer to that is 15 yes also. 16 MEMBER GRAHAM: Okay. Thank you. THE CHAIRPERSON: Dr. Giroux. 17 18 MEMBER GIROUX: Thank you. 19 I would like to address questions 20 first to the applicant. 21 Concerning the training and the operators, I would like to have a perspective of 22 23 numbers here. How many operators do you have in 24 total and how many new ones do you have per year? 25 Is there a high turnover rate or not and what is

StenoTran

the training requirement?

1

2 MR. MORTTZ: There are three 3 different operating crews at TRIUMF. One to run the 500 MeV cyclotron. There are five shifts of 4 three operators on that crew. There is another 5 6 crew for to operate the ISAC accelerators, which is not always operating around-the-clock these 7 days yet because it's still under development. 8 So I think there are about ten operators there. 9 And then there are the radioisotope production 10 cyclotron operators. I believe there are another 11 10 to 12 operators in that crew. 12

And the turnover rate in the past has been very low. There are typically one or two operators a year that are replaced.

16 MEMBER GIROUX: When you have new 17 operators, where do they come from? Do they come 18 directly from outside or do they move up through 19 the ranks?

20 MR. MORITZ: Well, the initial 21 operators, I mean initially most of the operators 22 were drawn from the technical people that had 23 helped to build the facility. But the newer ones 24 have come mostly as graduates from the -- out of 25 one of the technical colleges in British Columbia.

StenoTran

We have had also people coming 1 2 with experience from say the nuclear fuel cycle 3 people from -- reactor operators and so on. But very, very few. 4 MEMBER GIROUX: What you called in 5 6 your presentation, I believe, "shadowing training" 7 or something. Does that apply to new operators? MR. MORITZ: Yes. 8 MEMBER GIROUX: And your training 9 10 plan, which you have proposed and that staff has seen, does it focus mainly on the current 11 operators in terms of updating their abilities or 12 13 does it focus on new operators or what does it 14 focus on? 15 MR. MORITZ: Well, it is a general plan that would apply to all operators and we 16 17 would plan to basically requalify the operators 18 and also it would apply to any new operators that 19 were being hired. MEMBER GIROUX: My last question 20 on this, more out of curiosity. 21 How many hours per week on average 22 23 would you expect your operators to spend on 24 training? 25 MR. MORITZ: I don't know how to

StenoTran

1 answer that really.

2 DR. SHOTTER: Can I just actually 3 say, I mean if an operator is actually on the job it is essentially the whole day, because there is 4 obviously a continual dialogue between the senior 5 operators and the more junior people. 6 So this is indeed what one means by job shadowing, so that 7 there is dialogue the whole day. So in a sense 8 when a new operator comes in, the whole day is 9 10 actually spent in the training mode. That is what obviously job shadowing is. 11 I think that is an extremely good 12 13 way of actually learning how to operate a system 14 that is actually sort of fairly complex. I think that the record that the facility is actually sort 15 of running 90 per cent of the time -- and that is 16 17 an extremely high value in my experience in other 18 accelerators around the world, in fact 90 per cent is actually very high. 19 I think that does actually reflect 20 21 the quality of the training the operators have actually sort of gone through and I think the 22 23 shadowing is an extremely effective way of undertaking a training process. 24

25 MEMBER GIROUX: Thank you.

StenoTran

I will shift to a different line. 1 2 I am just curious about the arrangement between 3 the universities -- I won't raise again the issue I raised on Day 1 -- but you say that there are 4 conditions for withdrawal and I think you exposed 5 clearly that any university withdrawing would be 6 responsible for liabilities incurred before it 7 withdrew. 8 But what about decommissioning 9 Would a university withdrawing now still 10 costs. be responsible for decommissioning costs if it 11 occurs 15 or 20 years from now? 12 Is that 13 envisioned now? 14 DR. SHOTTER: I think my understanding is if, say for example, the facility 15 closed down, say in 15 years time and a university 16 has withdrawn now, that means to say there is 17 18 actually four universities. However, the 19 decommissioning costs must reflect the initial construction of the facility and the running of 20 21 the facility for the last 30 years. Μv understanding would be that that fifth university 22 23 that has, say, withdrawn, would in fact be liable 24 to a substantial part of the decommissioning 25 costs.

StenoTran

Of course it would have to be -- I 1 mean in 15 years time if there had been 2 3 developments of course, then the decommissioning costs would be greater than what they are now, so 4 it would be in proportion to the use that they 5 6 have actually made over the years. That is my understanding. 7 MEMBER GIROUX: That is something 8 you would want to put on paper I guess. 9 DR. SHOTTER: I think it is almost 10 My understanding is it is essentially 11 off paper. that is understood. 12 13 As Lutz has already referred to, I 14 think that is my understanding that it is in part of the venture agreement it is actually stated. 15 But, John, do you have any 16 17 comments on that? 18 DR. McDONALD: It is John McDonald. I am Chairman of the Board of 19 Management of TRIUMF. 20 21 There is a joint venture agreement which spells out the liabilities, and my 22 23 interpretation of that agreement would be exactly as the Director has described, that each 24 25 university would be responsible for activities up

StenoTran

to the time that they withdrew, and that would 1 include issues related to the cost of 2 3 decommissioning the facilities that were in existence at the time that they withdrew. 4 THE CHAIRPERSON: Ms MacLachlan. 5 6 MEMBER MacLACHLAN: Thank you. 7 Just to continue along that line of thinking with respect to the decommissioning 8 plan and any funds that would be required for 9 decommissioning, I got the impression that the 10 intent of TRIUMF was to recover or at least be 11 covered by Industry Canada for any decommissioning 12 13 funds. Is that correct? 14 DR. SHOTTER: Yes, that is 15 correct. MEMBER MacLACHLAN: You have a 16 letter from the head of the NRC -- I'm sorry --17 18 DR. SHOTTER: He is the President of NRC, yes. Dr. Carty. 19 20 MEMBER MacLACHLAN: Yes. Right. 21 But is there anything from Industry Canada to indicate or give TRIUMF any 22 23 assurance that Industry Canada would indeed cover these funds? 24 25 DR. SHOTTER: I think this matter

StenoTran

has actually been brought up at a meeting 1 essentially with TRIUMF and Industry Canada as 2 3 part of their regular Agency meetings. So therefore this matter is fully in the minutes of 4 those sort of meetings. 5 The statement about the best 6 efforts will be sort of made to try to actually 7 get the costs from the federal Industry Canada has 8 in fact -- they are in the minutes. 9 Industry 10 Canada is fully aware of that because they are part of the meeting. 11 The understanding 12 DR. McDONALD: 13 that we have, and it will be much better defined 14 once we have a formal statement of what the decommissioning costs are from the study that is 15 going on now, but as you heard in the 16 17 presentation, should it become necessary to 18 decommission all other activities would at that 19 point cease. 20 The understanding that I believe 21 the Agency Committee on TRIUMF, which is chaired by the President of NRC -- and incidently it is 22 23 NRC that is our conduit to Industry Canada --, but 24 Industry Canada is represented on that Agency 25 Committee, and I believe the understanding is

StenoTran

clear that TRIUMF has an operating budget that in 1 the event of a decommissioning the likely scenario 2 3 would be that operating budget would simply continue through the year required -- or whatever 4 time required for decommissioning, but should, for 5 any reason, that not happen, then the universities 6 are ultimately liable. 7 That is really the statement as it 8 We would love to have something in 9 is now. 10 writing from Industry Canada of course. We don't have that right now. 11 12 MEMBER MacLACHLAN: Have any of 13 the universities earmarked funds for this 14 contingency? 15 DR. McDONALD: The universities --I can't speak for all of them. Carleton, for 16 17 example, has just been added to the group. 18 But I know at my own university, 19 and I'm sure it has happened at every one of them that have been involved for a period, the 20 University Board of Governors have reviewed the 21 situation, understand their ownership and 22 23 understand their liabilities very clearly at the Board level. 24 25 So I am quite confident the answer

StenoTran

1 to that is yes.

2 DR. HAMDULLAHPUR: If I could add 3 a word.

In addition to my TRIUMF duties I 4 am the Vice-President of Research at Carleton 5 6 University, one of the five members of this joint venture, and we were fully aware of the 7 decommissioning cost in case Industry Canada did 8 not come up with the funds. So we are fully aware 9 10 of our obligations in terms of decommissioning and we accept it. 11

MEMBER MacLACHLAN: It is one 12 13 thing to accept a potential future liability 14 conceptually but it is another thing to build that into a budget. Has that translation taken place? 15 DR. HAMDULLAHPUR: This was 16 17 discussed and the university -- please don't quote 18 me on this -- has a substantial contingency fund 19 in case such event occurs to fund the decommissioning, its portion of the 20 21 decommissioning cost. Okay. Let me 22 MEMBER MacLACHLAN: 23 come at it from a different perspective, then. 24 What is the anticipated lifespan

25 of this facility?

StenoTran

That is, of course, 1 DR. SHOTTER: 2 very difficult to actually answer because any 3 research facility is a dynamic organization and certainly at the moment TRIUMF is going through a 4 very dynamic stage of development. In fact, now 5 it is one of the top laboratories in the world for 6 its particular area of science. It is in fact 7 leading the world. Many countries around the 8 world would like to catch up to TRIUMF. 9 10 But I think in fact probably, because of the developments that have taken place 11 in the last sort of few years, we have at least 12 13 about a 10-year lead over the rest of the world in 14 the particular science that we are conducting. So I certainly think that we have a 10-year lifespan. 15 If the laboratory is sufficiently 16 17 dynamic during that 10 years I am sure it can even 18 continue beyond that. So I would predict -- of course it 19 is very difficult to predict into the future, but 20 I would predict that it probably has at least a 21 lifespan of 15 years and even more. 22 23 MEMBER MacLACHLAN: Okay. 24 Thank you. 25 I have a question of staff.

StenoTran

Staff mentioned that the training 1 plan submitted by TRIUMF was adequate but 2 3 ambitious. Could you tell us a little bit more about why you think the plan is ambitious? 4 In what areas is it ambitious? 5 6 And is it the plan that is ambitious or its implementation? If it is its 7 implementation, how does that marry with the fact 8 that there is a facility that is up and running 9 10 and has been running and operational at what appear to be fairly high success rates? 11 I am going to ask 12 MR. HOWDEN: 13 John Power to address that question. 14 MR. POWER: Our emphasis on the area of training has been for TRIUMF to take a 15 16 systematic approach. So when we say the plan is 17 adequate, we mean that it is adequately 18 implementing the systematic approach to training as we see it and as we have discussed with TRIUMF. 19 I think the ambitious part of it 20 21 was the -- essentially TRIUMF has committed to everything we would ask them to do, but like the 22 23 time schedule in which they say can do that seemed 24 a bit ambitious to us. We would be very happy if 25 they succeed, but it seemed ambitious. So we were

StenoTran

intending to follow up just to make sure they 1 stayed on schedule. 2 3 MEMBER MacLACHLAN: So if T understand you correctly, the ambitiousness is the 4 systematic commitment to paper in a disciplined 5 6 way their approach to training, as opposed to the quality of training of the operators themselves? 7 MR. POWER: Yes. 8 9 MEMBER MacLACHLAN: Okay. 10 Thank you. Back to TRIUMF again. You have 11 set up a couple of task forces, one with respect 12 13 to quality assurance, the other one with respect 14 to housekeeping. What are the tasks for those task forces and their timelines for completing 15 those tasks? 16 17 DR. SHOTTER: As regards the 18 quality assurance, I consider the quality of work that comes out of TRIUMF to be of the highest 19 As Lutz has actually referred to, TRIUMF 20 level. 21 is an international laboratory and it is highly respected around the world. 22 We do a lot of work for other 23 laboratories around the world, in particular the 24 25 European CERN Laboratory, which is a truly

StenoTran

international laboratory. We undertake work for 1 that, and in fact even this week I have a letter 2 3 from the authorities there stating how pleased they are with some of the work that we have 4 actually done for the CERN Laboratory. 5 6 So I think the quality assurance, actually where it matters, is in fact very high at 7 TRIUMF. 8 Perhaps what we haven't actually 9 sort of done is followed again the documentation 10 of quality assurance. Where in fact that helps us 11 to improve our standards, then I am very keen, 12 where it indeed does actually help us to improve 13 14 the very high standards that already exist. 15 So, yes, we are looking actively into implementing some, as it were, paper trail in 16 17 order to actually sort of improve the high level 18 of work that is already there. As regards sort of housekeeping, 19 as Lutz has already referred to, TRIUMF is a very 20 dynamic research facility and, as such, perhaps 21 people work sort of faster than in fact the 22 23 housekeeping would sometimes sort of dictate. They should essentially sort of clear up behind 24 25 them. They tend to actually sort of go faster

StenoTran

than in fact perhaps is good from the point of 1 view of keeping things tidy. 2 3 I, as the new post as Director of TRIUMF, have actually sort of gone around the 4 actual site and I am encouraging people to maybe 5 stop their active work and in fact sort of maybe 6 tidy up after them. 7 But I think that this maybe -- I 8 think when the inspectors have actually come 9 10 sometimes they have remarked about sort of housekeeping, maybe it is a little bit untidy in 11 certain areas. As I said, I think that this is a 12 13 result of a very dynamic research environment. 14 But, yes, I think that we can improve in this field and in fact I have 15 instigated certain organization changes to ensure 16 17 that we do improve in this field. 18 But, as I emphasize, we are a 19 dynamic place. We are not essentially providing a static service, it is very dynamic, and therefore 20 21 to some extent this will always be a slight problem, but I am addressing it. 22 23 MEMBER MacLACHLAN: Thank you. Dr. Giroux. 24 THE CHAIRPERSON: 25 MEMBER GIROUX: Continuing along

StenoTran

the same lines, in your document the applicant has 1 a number of statements which are a bit challenging 2 3 for staff and I would like to explore some of 4 them. On page 10 concerning quality 5 assurance you mentioned that you sometimes receive 6 7 conflicting advice from staff. Could you give me an example or two of that? 8 9 MR. MORITZ: Yes. I can answer 10 that in that when the new CNSC regulations came out, as you know there is a requirement in those 11 regulations that nuclear facilities -- all nuclear 12 facilities I think -- have to have a quality 13 14 assurance program. The statement is unqualified. It simply says that there must be a quality 15 16 assurance plan or program. So our question to the CNSC staff 17 18 was basically that we wanted to know how such a program -- what it needed to address and was it to 19 be addressing only safety issues or was it to be a 20 21 blanket program that covered all aspects of the

In that respect we had one CNSC staff member come and basically say that it was unqualified, that we needed to address all aspects

operation.

22

StenoTran

of the operation.

1

2 When we requested that someone 3 from the CNSC come and give us an explanation of their expectations, a different person came to 4 5 visit, and that person quite clearly said that 6 they were only concerned about safety issues, just that the quality assurance plan needed to apply 7 only to safety issues. 8 So we were somewhat taken aback at 9 10 that point because we had geared up and had people come to the presentation by the CNSC staff person 11 from across TRIUMF and, quite frankly, I was 12 13 somewhat disappointed or taken aback because when 14 he said that many people in the room just turned off because they thought that it didn't apply to 15 16 them. 17 So we have had conflicting views 18 on what is expected of us. That is the main 19 MEMBER GIROUX: 20 issue that you were referring to in your original 21 document? 22 MR. MORITZ: Yes. 23 MEMBER GIROUX: Thank you. I would like staff to react. 24 25 Also, on the same page they say

StenoTran

that they find it curious that staff is imposing a 1 deadline instead of providing guidance. Could you 2 3 also clarify your position? MR. HOWDEN: Barclay Howden 4 I will address both of those points. 5 speaking. 6 In our opinion, we have been consistent in our essential QA requirements and 7 there is consensus between all our staff on these 8 requirements. We have communicated these in 9 10 writing. Although it can happen, and we are 11 hearing, our intentions are not to give mixed or 12 13 conflicting messages. So we are committed to 14 continued dialogue with TRIUMF to make sure there is a clear understanding of our requirements and 15 that we clarify any fuzzy messages. 16 17 I think the important thing is 18 that safety is critical, but I think the other 19 thing is overall management can impact safety, and so I think those messages may not have been well 20 delivered. But, as I say, we are committed to 21 continued dialogue to make sure that they have a 22 23 clear understanding of our requirements. In terms of QA, we do see it as a 24 25 continuous improvement-type activity because the

StenoTran

focus here is on ALARA. However, we need to 1 achieve minimum levels so that we can say that 2 3 that minimum level has been achieved. So what we anticipate is that the 4 license condition, when met, shows that a minimum 5 6 level of QA has been put in place. But we would not want them to stop there. We think that they 7 should continue looking at ALARA and go for the 8 continuous improvement. 9 So we don't totally disagree with 10 them, but we have to be able to draw a line that 11 says they have met the license condition and have 12 met the requirements of the regulations. 13 14 MEMBER GIROUX: Thank you. 15 My other question is, there are statements on page 7 saying essentially that 16 17 staff -- they don't use those words -- is over 18 zealous in applying regulations to what is, 19 according to the applicant, a small risk operation and that for fear of being accused of lack of 20 diligence they are applying very strict standards 21 to them. 2.2 23 Could you answer that question? 24 MR. HOWDEN: Barclay Howden again.

47

StenoTran

There are two main aspects that we

look at when we form our assessment of whether an applicant is qualified or not. One is, we look at past performance. Two, we look at systems and programs they have in place to ensure the good performance continues or that poor or fair performance improves. So much of our focus is on the second area.

8 In the context of risk, what we 9 have done with TRIUMF is we have determined that 10 they do indeed have a low risk profile based on 11 their hazards, which are well characterized in the 12 mitigation measures they have in place. I think 13 the past performance has been demonstrated.

What we are doing is looking towards the future and what we see is there is a lack of formality with regard to their management systems. It doesn't mean they are not there, but there is a lack of formality and they are making efforts to go there.

20 This is where the focus of our 21 attention has been. We see the need for 22 continuous improvement to ensure ALARA is 23 maintained.

With regard to being over zealous,
we have -- for quality management, for example, we

StenoTran

have requirements that have been submitted to them 1 that talk about what the elements are. 2 These 3 elements are the same that are going out to facilities with similar risk profiles. 4 Where it changes is when you get 5 into the details of the complexity and the risks 6 7 posed. In our opinion, we are trying to 8 ensure that our requirements match the 9 complexities and the risks. 10 Dr. Aly, who is the line manager 11 on this, would like to comment as well. 12 13 DR. ALY: I guess TRIUMF tried to 14 give the impression that we treated them like 15 power reactors and I would like to assure the Commission that we are not doing that. We are not 16 17 treating them like a power reactor by any means. 18 Being a Class IB facility does not 19 mean they are being treated like power reactors, 20 because some of the Class IA facilities that are much smaller than TRIUMF, like SLOWPOKE reactors 21 for instances, so we apply appropriate level of 22 23 regulation to the facility based on the risk that Mr. Howden just mentioned, and we don't intend to 24 25 do that.

StenoTran

MEMBER GIROUX: I have one more 1 2 question, one comment coming out of these answers. 3 What I'm thinking is, on the comments on the housekeeping and the lack of 4 formality, I think they go together. Even though 5 6 it is a dynamic research enterprise and that you 7 are always doing things new, you still want to have -- well, staff is looking for minimum of 8 formality and a minimum of housekeeping also just 9 10 to make sure that the risks are maintained very That is my understanding of these two 11 low. 12 issues. I have another question for staff, 13 14 just a clarification. 15 In the document that we have today, 34.B I think, you say that the licence 16 would be issued to the five universities. 17 Οn 18 Day 1 you mentioned that the licence would be issued to the Governors of the five universities. 19 Is that the same thing? Is that the same wording? 20 21 DR. ALY: It's the same wording. MEMBER GIROUX: 22 Thank you. 23 THE CHAIRPERSON: I just wish to 24 acknowledge that the applicant, Dr. Giroux, would 25 like to comment on your previous question if you

StenoTran

1

2

are agreeable to that.

3 MR. MORITZ: I would just like to 4 clear up any misunderstanding about that 5 statement. I think we have had a long 6 relationship with CNSC staff and previously the 7 AECB staff and those relations have, for the most 8 part, been very cordial.

9 We respect the dedication of the staff and their diligence and we would not want to 10 imply at all any fault in their behaviour. 11 It's simply I think that the point we were trying to 12 13 make was that the regulations are written in such 14 a way that they apply equally to facilities of a very great degree of difference and risk and it is 15 left to the CNSC staff to interpret how to apply 16 17 those regulations.

18 I think it's only human nature 19 that they apply in such a way that is the most conservative way as they would not be very willing 20 21 to have a more relaxed view because the risk is less because obviously that is their role, to 22 23 control us and I think that was the point we were trying to make, that it's just that the 24 25 regulations are so general and apply to all types

StenoTran

51

MEMBER GIROUX:

Sure.

of facilities that it's a difficult job for the 1 CNSC staff to find the right point of balance on 2 3 how to interpret them for a facility such as TRIUMF because TRIUMF is unique in Canada. There 4 are not other facilities like it. That was the 5 point we were trying to make 6 7 THE CHAIRPERSON: I don't want to 8 start a debate and let me assure you I will not let that happen here. 9 However, I will allow one more 10 comment from CNSC staff, if they wish on this, and 11 that matter will be closed. 12 13 MR. HOWDEN: We don't have any 14 further comments. 15 THE CHAIRPERSON: Mr. Graham. 16 MEMBER GRAHAM: A question I have 17 to the applicant: What was your budget in 2001 to 18 operate this facility? MR. SHOTTER: In 2001 it was \$40 19 million. 20 21 MEMBER GRAHAM: What is it in 2002?22 MR. SHOTTER: It's at about the 23 24 same level. 25 MEMBER GRAHAM: What is it going

StenoTran

53

to be for -- I presume your calendar years are --1 MR. SHOTTER: Well it's April to 2 3 April. MEMBER GRAHAM: I quess you put in 4 place in your submission this morning certain 5 things you are going to be doing and certain other 6 aspects with regard to safety, with regard to 7 training, with regard to insurance, and so on, and 8 those things. 9 How much extra funds are you 10 attributing to do these extra things that you are 11 12 qoing to do? In fact, for this 13 MR. SHOTTER: 14 particular year we are in the active process of 15 drawing up the budget now. In fact, Lutz has actually sort of made a presentation to us 16 actually even this week for the extra resources 17 18 needed to undertake sort of certain actions that we have already sort of stated. 19 These funds we are looking actively at. 20 21 I can assure you that that is high on our priority list. 22 23 MEMBER GRAHAM: Approximately how 24 much additional funds are you looking at? MR. SHOTTER: Well, I think for 25

StenoTran

the -- well maybe, Lutz, you should answer. 1 2 MR. MORITZ: The total budget for 3 the safety aspects which is simply a materials budget -- this does not count the salaries of 4 various people -- is the resources that are 5 6 required in terms of consultants, or whatever, and things like that -- the total budget for the 7 safety operations is approximately \$300,000 a year 8 and we have asked for an increase, I think, of 9 something like \$60,000. 10 MEMBER GRAHAM: But that does not 11 include salaries. 12 13 MR. MORTTZ: No. 14 MEMBER GRAHAM: Are you adding any 15 additional staff? 16 MR. MORITZ: We are in the process 17 of hiring one staff, but that's unrelated to some 18 of these questions that are raised today here. 19 MEMBER GRAHAM: The commitment from the partners, the partner universities toward 20 21 the \$40 million or the proposed additional funds, annual budget or the additional funds that will be 22 23 required, is there a sense that all will buy in? 24 MR. SHOTTER: Sorry, I don't 25 understand the question.

StenoTran

MEMBER GRAHAM: I guess what I am 1 saying is if you need an extra million or two 2 3 million, or whatever it's going to come at, are all of the university participants, are they all 4 5 agreeable? MR. SHOTTER: No. 6 In fact, this 7 would actually have to come out a fixed budget. Our budget is fixed over five years. So any extra 8 money that is actually needed in any areas has to 9 come out of the fixed budget. So what goes in one 10 budget will have to come out of another section. 11 MEMBER GRAHAM: I didn't realize 12 13 that. So you are saying that your budget is fixed 14 at \$40 million approximately, \$40 million a year for five years. When are the five years up? 15 16 MR. SHOTTER: The five years are 17 up in 2005. 18 MEMBER GRAHAM: So you are just 19 into that. Okay. Just one question with regard to 20 21 decommissioning, and I know it has been talked about a lot, but there has been a company hired to 22 23 do this, Beacon International. The report will be 24 out by mid-2002. Funds have been allocated to pay 25 for this.

StenoTran

My question is: Will the study 1 give all of the details of exactly what the 2 3 decommissioning costs will be and at what years, 2015 or 2020, or what it is? 4 MR. SHOTTER: Yes, in fact it 5 6 should give all the details that are needed at the present time. Now, in fact, if we pay extra funds 7 then this can be kept active as each year goes by. 8 But this will cost a lot of extra money. 9 By the way, this cost of 10 decommissioning is actually quite considerable and 11 when the budget was put into place, first of all 12 13 for this particular five years, we did not understand the need for that because we were not 14 asked to do that. 15 So therefore this is an extra cost 16 17 that has to be found out of the other parts of the 18 budget which mean to say the research actually is less because of that. 19 MEMBER GRAHAM: You are talking 20 about the \$225,000? 21 MR. SHOTTER: Yes, but it will 22 23 actually cost more than that. When the final bills come in it, in fact, will cost more than 24 25 that.

StenoTran

MEMBER GRAHAM: In your \$40 1 2 million annual budget, do you have any contingency 3 funding that you are setting aside for decommissioning? 4 5 MR. SHOTTER: No. 6 MEMBER GRAHAM: Will the study 7 also identify where the guarantees will come from or what the responsibilities will be? The reason 8 I ask that is the NRC letter that you have, or the 9 10 agreement that you have right now from NRC, is a laudable one, but it doesn't really -- it's not 11 really -- the way it reads in our presentation 12 it's not really binding. 13 14 MR. SHOTTER: Yes, that is my understanding. The decommissioning cost is 15 essentially a technical undertaking. 16 That actually will identify what the technical needs 17 18 are and what the costs are to meet the decommissioning sort of requirements. 19 But essentially my understanding is that it is a 20 21 technical effectively study. MEMBER GRAHAM: One other 22 23 question, I guess, to staff. When the study is 24 complete, when all of the work has been done on 25 it, who will have the review? Will it come as a

StenoTran

58

meeting item or will it come before the Commission 1 again, or will it be strictly dealt with by staff? 2 3 MR. HOWDEN: I will ask Dr. Aly to respond. 4 DR. ALY: We will deal with that 5 6 the same way we dealt with similar facilities. Once agreements on financial guarantees have been 7 reached by the applicant, we will bring that to 8 the attention of the Commission for a decision. 9 THE CHAIRPERSON: Ms MacLachlan. 10 MEMBER MacLACHLAN: 11 Yes, just a 12 very brief question to the applicant. 13 You mentioned that you have a 14 budget of \$40 million a year. Does that money 15 come from the participant universities, or does that money come from elsewhere, and what about the 16 revenue side? You mentioned the activities that 17 18 are taking place through TRIUMF. Do you derive revenue from any of those activities for outside 19 20 clients? 21 Yes. The \$40 MR. SHOTTER: million is federal funds. Yes, there is a certain 22 23 level of funds that actually sort of flow from technology and sort of transfer activities. 24 Most 25 of these funds are used essentially to pay for

StenoTran

certain things like the infrastructure charge that we have to actually pay to UBC because we are on the UBC campus, which we cannot use federal funds for.

1

2

3

4

5 So there are various sort of 6 charges like this that we have to actually find 7 extra sort of money for. It cannot be federal 8 funds and the technology transfer does provide 9 such funds to undertake these obligations.

10MEMBER MacLACHLAN: But it's not11an economically self-sufficient operation.

MR. SHOTTER: I think it's more or 12 13 less sort of -- it doesn't actually cost TRIUMF 14 money to run the technology transfers, to answer your question. There is a positive flow back to 15 TRIUMF as a result of these activities, and as I 16 17 have actually said, the monies that flow back 18 enable us to actually fulfil certain obligations 19 we couldn't operate by if we didn't actually have these extra funds. So it is a positive 20 21 contribution.

I think actually TRIUMF -- I have experience with many laboratories around the world and TRIUMF has been, and is, extremely successful in technology transfer. I think it's one of the

StenoTran

best examples of this I know from many sort of 1 countries around the world. 2 3 MEMBER MacLACHLAN: Could you just clarify for me what you mean specifically by 4 "technology transfer"? 5 6 MR. SHOTTER: Yes, indeed. The 7 high level of expertise that is actually gained by people at TRIUMF is indeed of interest to various 8 industrial concerns. So for example a particular 9 10 industry could actually come to us and consult us in certain problems that they actually have, and 11 12 because of the unique experience that we have, we can actually sort of transfer our expertise to 13 14 industry. 15 This is essentially what technology transfer means. That can be in the 16 17 whole range of industries from the sort of health 18 providers right away to sort of food sterilization. There is a wide range of 19 industrial activities that have actually made use 20 21 of TRIUMF's unique expertise. That's what we mean by technology transfer. 22 23 MEMBER MacLACHLAN: Thank you. 24 THE CHAIRPERSON: Thank you very 25 much.

StenoTran

I would just like to make a couple 1 of comments from the Chair. First of all, since 2 3 it was the Chair who asked you to come, I would like to show my appreciation to particularly the 4 members of the Board of Governors for coming. 5 Ι 6 appreciate that very much. We didn't ask any specific questions with regards to the Safety and 7 Security Committee, but we are very pleased that 8 this exists and we think that this is an 9 appropriate model for an institution. 10 There have been some references 11 with regards to differences between research 12 13 institutions and other institutions and we take 14 that into account in looking at this. However, I would like just to note that three Members of this 15 Commission, including myself, have been both on 16 the bench and in research institutions. 17 So we do 18 understand research, and since I ran two ISO-qualified research laboratories I do feel that 19 we are able to know the difference and to 20 understand people coming in and out of 21 institutions. 2.2 23 That said, there appears to me 24 some issues with regards with housekeeping and

25 quality assurance. Perhaps some of the

StenoTran

definitions that we are using are not clearly 1 understood. Housekeeping is not the same as 2 3 accidents in our mind, and there has been, I think, a great change in thinking towards how 4 5 systems being put in place, as Mr. Howden has 6 noted, have sought to increase safety systems that don't necessarily result in specific short-term 7 pay off, but in fact are systems of management 8 that are essential to operations of facilities in 9 10 general. So we do appreciate that.

So I do appreciate your coming. 11 Ι do appreciate this emphasis and I do urge the 12 13 institution to continue to have dialogue with the 14 CNSC staff and perhaps with other institutions in terms of this growing body of knowledge as to 15 management, culture, housekeeping, quality 16 17 assurance and what this means because things have 18 really changed.

19 My last comment is with regards to 20 decommissioning. When we look at public interest 21 with regards to all the facilities that we 22 regulate, the issues of decommissioning have 23 become more and more important. So I guess I can 24 say it isn't something that will go away, that the 25 issues of human protection, but also protection of

StenoTran

the environment and dealing with this are probably 1 one of the major challenges facing the industry in 2 3 the large sense of the word. With that, I would like to just 4 turn it over to the Secretary for completion of 5 6 this hearing. 7 M. LEBLANC: Merci, madame la présidente. 8 9 This completes the record for the 10 public hearing on the matter of an application by TRIUMF for a licence to operation Class I and II 11 particle Accelerator facilities at its site in 12 13 Vancouver, British Columbia. The Commission will deliberate and 14 will publish its decision in due course. It will 15 be posted on the CNSC website as well as 16 distributed to participants. 17 18 Merci. 19 Thank you very THE CHAIRPERSON: 20 much. 21 We will take a ten-minute break. So we will start at two minutes after ten with the 22 23 next hearing. 24 Thank you. 25 --- Upon recessing at 9:52 a.m.

StenoTran